EcoDrugPlus

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSRBIG00000044149
Gene Symbol: HTR2B
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSRBIG00000033910
Gene Symbol: HTR3A
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSRBIG00000044677
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3c

Ensembl ID : ENSRBIG00000036099
Gene Symbol: HTR3C
2 Cross references
57 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3d

Ensembl ID : ENSRBIG00000032796
Gene Symbol: HTR3D
3 Cross references
57 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSRBIG00000033134
Gene Symbol: HTR3E
4 Cross references
37 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSRBIG00000042388
Gene Symbol: HTR4
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSRBIG00000038906
Gene Symbol: HTR5A
4 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSRBIG00000031001
Gene Symbol: HTR6
4 Cross references
114 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSRBIG00000017965
Gene Symbol: HTR7
4 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L12-Like

Ensembl ID : ENSRBIG00000023242
Gene Symbol: LOC108519429
2 Cross references
160 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L14 Pseudogene

Ensembl ID : ENSRBIG00000007466
Gene Symbol: LOC108524937
1 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).